The DOI matches its Crossref record; 116 of the 116 references it cites were found in a registry or an index.
Epigenetic modifications as therapeutic targets
Open accessAbstract
Epigenetic modifications work in concert with genetic mechanisms to regulate transcriptional activity in normal tissues and are often dysregulated in disease. Although they are somatically heritable, modifications of DNA and histones are also reversible, making them good targets for therapeutic intervention. Epigenetic changes often precede disease pathology, making them valuable diagnostic indicators for disease risk or prognostic indicators for disease progression. Several inhibitors of histone deacetylation or DNA methylation are approved for hematological malignancies by the US Food and Drug Administration and have been in clinical use for several years. More recently, histone methylation and microRNA expression have gained attention as potential therapeutic targets. The presence of multiple epigenetic aberrations within malignant tissue and the abilities of cells to develop resistance suggest that epigenetic therapies are most beneficial when combined with other anticancer strategies, such as signal transduction inhibitors or cytotoxic treatments. A key challenge for future epigenetic therapies will be to develop inhibitors with specificity to particular regions of chromosomes, thereby potentially reducing side effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MicroRNA signatures in human cancers
Calin, G. A., & Croce, C. M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1997 · Cited by 7,590
Conversion of 5-Methylcytosine to 5-Hydroxymethylcytosine in Mammalian DNA by MLL Partner TET1
Tahiliani, M., Koh, K. P., Shen, Y., Pastor, W. A., Bandukwala, H., Brudno, Y., Agarwal, S., Iyer, L. M., Liu, D. R., Aravind, L., et al. (2009) · Science · doi:10.1126/science.1170116 · Cited by 5,836 · cited 1×
“In addition, it was recently shown that 5- methylcytosine can be converted into 5-hydroxymethylcytosine by members of the TET protein famil”
BackgroundHuman DNA methylomes at base resolution show widespread epigenomic differences
Lister, R., Pelizzola, M., Dowen, R. H., Hawkins, R. D., Hon, G., Tonti-Filippini, J., Nery, J. R., Lee, L., Ye, Z., Ngo, Q.-M., et al. (2009) · Nature · doi:10.1038/nature08514 · Cited by 4,673
Jones, P. A., & Baylin, S. B. (2007) · Cell · doi:10.1016/j.cell.2007.01.029 · Cited by 4,515
Self-citationLysine acetylation targets protein complexes and co-regulates major cellular functions
Choudhary, C., Kumar, C., Gnad, F., Nielsen, M. L., Rehman, M., Walther, T. C., Olsen, J. V., & Mann, M. (2009) · Science · doi:10.1126/science.1175371 · Cited by 4,040 · cited 1×
“Furthermore, because HDAC inhibitors only target ∼10% of all acetylation site”
BackgroundEpigenetics in human disease and prospects for epigenetic therapy
Egger, G., Liang, G., Aparicio, A., & Jones, P. A. (2004) · Nature · doi:10.1038/nature02625 · Cited by 3,232
Self-citationUnique microRNA molecular profiles in lung cancer diagnosis and prognosis
Yanaihara, N., Caplen, N., Bowman, E., Seike, M., Kumamoto, K., Yi, M., Stephens, R. M., Okamoto, A., Yokota, J., Tanaka, T., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.01.025 · Cited by 3,023 · cited 1×
“This suggests that miR-155 is a promising target for LNA–anti-miRNA therapy ( Table 1”
BackgroundCauses and consequences of microRNA dysregulation in cancer
Croce, C. M. (2009) · Nature Reviews Genetics · doi:10.1038/nrg2634 · Cited by 2,998
Epigenetic modifications and human disease
Portela, A., & Esteller, M. (2010) · Nature Biotechnology · doi:10.1038/nbt.1685 · Cited by 2,836
Fenaux, P., Mufti, G. J., Hellstrom-Lindberg, E., Santini, V., Finelli, C., Giagounidis, A., Schoch, R., Gattermann, N., Sanz, G., List, A., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70003-8 · Cited by 2,663 · cited 1×
“5-Azacytidine (5-Aza-CR; Vidaza; azacitidine), a nucleoside analog that is incorporated into RNA and DNA, is approved to treat patients with high-risk myelodysplastic syndromes (MDS) and successful clinical results have recently been reported ( Tables 2 and 3”
Background
Cited by
Shrestha, S., & Offer, S. M. (2016) · Medical Epigenetics · doi:10.1159/000444713 · Cited by 8,914
A decade of exploring the cancer epigenome—biological and translational implications
Baylin, S. B., & Jones, P. A. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3130 · Cited by 2,871
Self-citationEpigenetic modifications and human disease
Portela, A., & Esteller, M. (2010) · Nature Biotechnology · doi:10.1038/nbt.1685 · Cited by 2,836
Roulois, D., Loo Yau, H., Singhania, R., Wang, Y., Danesh, A., Shen, S. Y., Han, H., Liang, G., Jones, P. A., Pugh, T. J., et al. (2015) · Cell · doi:10.1016/j.cell.2015.07.056 · Cited by 1,527
Self-citationEpigenetic protein families: a new frontier for drug discovery
Arrowsmith, C. H., Bountra, C., Fish, P. V., Lee, K., & Schapira, M. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3674 · Cited by 1,327
“DAC10-1(1) HAC10-5 HD10-2(1) H D AC (6)(1) H D A C 6(2) D A C 9 H D A C 5 HD AC 4 HD AC 7 HD AC 2 HD AC1 HDAC3 HAC8 HAC11 SIRT7 SIRT6 -2 SIR T6 -1 SI RT 64”
BackgroundInfluentialEpigenetic Determinants of Cancer
Baylin, S. B., & Jones, P. A. (2016) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a019505 · Cited by 1,226
Self-citationGene Body Methylation Can Alter Gene Expression and Is a Therapeutic Target in Cancer
Yang, X., Han, H., De Carvalho, D. D., Lay, F. D., Jones, P. A., & Liang, G. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.07.028 · Cited by 1,199
Self-citationCancer Genetics and Epigenetics: Two Sides of the Same Coin?
You, J. S., & Jones, P. A. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.06.008 · Cited by 1,167
Self-citationFolate and DNA Methylation: A Review of Molecular Mechanisms and the Evidence for Folate's Role
Crider, K. S., Yang, T. P., Berry, R. J., & Bailey, L. B. (2012) · Advances in Nutrition · doi:10.3945/an.111.000992 · Cited by 1,015
Serrano-Gomez, S. J., Maziveyi, M., & Alahari, S. K. (2016) · Molecular Cancer · doi:10.1186/s12943-016-0502-x · Cited by 814
DNA methylation profiling in the clinic: applications and challenges
Heyn, H., & Esteller, M. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3270 · Cited by 746
Bekkering, S., Quintin, J., Joosten, L. A. B., van der Meer, J. W. M., Netea, M. G., & Riksen, N. P. (2014) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.114.303887 · Cited by 726
MethSurv: A Web Tool to Perform Multivariable Survival Analysis Using DNA Methylation Data
Modhukur, V., Iljasenko, T., Metsalu, T., Lokk, K., Laisk-Podar, T., & Vilo, J. (2018) · Epigenomics · doi:10.2217/epi-2017-0118 · Cited by 645
Hon, G. C., Hawkins, R. D., Caballero, O. L., Lo, C., Lister, R., Pelizzola, M., Valsesia, A., Ye, Z., Kuan, S., Edsall, L. E., et al. (2012) · Genome Research · doi:10.1101/gr.125872.111 · Cited by 583
Epigenetic mechanisms in neurological disease
Jakovcevski, M., & Akbarian, S. (2012) · Nature Medicine · doi:10.1038/nm.2828 · Cited by 450
Editing the epigenome: technologies for programmable transcription and epigenetic modulation
Thakore, P. I., Black, J. B., Hilton, I. B., & Gersbach, C. A. (2016) · Nature Methods · doi:10.1038/nmeth.3733 · Cited by 451
Recent developments of HDAC inhibitors: Emerging indications and novel molecules
Bondarev, A. D., Attwood, M. M., Jonsson, J., Chubarev, V. N., Tarasov, V. V., & Schiöth, H. B. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14889 · Cited by 416
Targeting protein–protein interactions as an anticancer strategy
Ivanov, A. A., Khuri, F. R., & Fu, H. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.04.007 · Cited by 401
“Furthermore, It has recently been shown that epigenomic re-programming is a critical part of cancer development [7], and PPIs involved in epigenomic dysregulation, such as SMARCA4 interactions, have been described [8].”
BackgroundRole of microbiota-derived short-chain fatty acids in cancer development and prevention
Mirzaei, R., Afaghi, A., Babakhani, S., Sohrabi, M. R., Hosseini-Fard, S. R., Babolhavaeji, K., Khani Ali Akbari, S., Yousefimashouf, R., & Karampoor, S. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111619 · Cited by 394
BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia
Ott, C. J., Kopp, N., Bird, L., Paranal, R. M., Qi, J., Bowman, T., Rodig, S. J., Kung, A. L., Bradner, J. E., & Weinstock, D. M. (2012) · Blood · doi:10.1182/blood-2012-02-413021 · Cited by 374
Epigenetic Therapeutics: A New Weapon in the War Against Cancer
Ahuja, N., Sharma, A. R., & Baylin, S. B. (2016) · Annual Review of Medicine · doi:10.1146/annurev-med-111314-035900 · Cited by 363
The emerging role of mass spectrometry-based proteomics in drug discovery
Meissner, F., Geddes-McAlister, J., Mann, M., & Bantscheff, M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00409-3 · Cited by 341
The future of epigenetic therapy in solid tumours—lessons from the past
Azad, N., Zahnow, C. A., Rudin, C. M., & Baylin, S. B. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.42 · Cited by 335
Epigenetic drivers of tumourigenesis and cancer metastasis
Chatterjee, A., Rodger, E. J., & Eccles, M. R. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.08.004 · Cited by 328
Liang, J., & Shang, Y. (2013) · Annual Review of Physiology · doi:10.1146/annurev-physiol-030212-183708 · Cited by 314
CRISPR/Cas9-based engineering of the epigenome
Pulecio, J., Verma, N., Mejía-Ramírez, E., Huangfu, D., & Raya, A. (2017) · Cell Stem Cell · doi:10.1016/j.stem.2017.09.006 · Cited by 300
Phuengkham, H., Ren, L., Shin, I. W., & Lim, Y. T. (2019) · Advanced Materials · doi:10.1002/adma.201803322 · Cited by 306
New methods in the diagnosis of cancer and gene therapy of cancer based on nanoparticles
Zaimy, M. A., Saffarzadeh, N., Mohammadi, A., Pourghadamyari, H., Izadi, P., Sarli, A., Moghaddam, L. K., Paschepari, S. R., Azizi, H., Torkamandi, S., et al. (2017) · Cancer Gene Therapy · doi:10.1038/cgt.2017.16 · Cited by 289
DNA Methylation Screening Identifies Driver Epigenetic Events of Cancer Cell Survival
De Carvalho, D. D., Sharma, S., You, J. S., Su, S.-F., Taberlay, P. C., Kelly, T. K., Yang, X., Liang, G., & Jones, P. A. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.03.045 · Cited by 285
Self-citationFuchs endothelial corneal dystrophy: The vicious cycle of Fuchs pathogenesis
Ong Tone, S., Kocaba, V., Böhm, M., Wylegala, A., White, T. L., & Jurkunas, U. V. (2021) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2020.100863 · Cited by 284
Yuille, S., Reichardt, N., Panda, S., Dunbar, H., & Mulder, I. E. (2018) · PLOS ONE · doi:10.1371/journal.pone.0201073 · Cited by 257
Cancer Epigenetics: An Introduction
Kanwal, R., Gupta, K., & Gupta, S. (2015) · Methods in Molecular Biology · doi:10.1007/978-1-4939-1804-1_1 · Cited by 259
The Role of DNA Methylation in Cancer
Lakshminarasimhan, R., & Liang, G. (2016) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-319-43624-1_7 · Cited by 259
Polycystic ovary syndrome is transmitted via a transgenerational epigenetic process
Mimouni, N. E. H., Paiva, I., Barbotin, A.-L., Timzoura, F. E., Plassard, D., Le Gras, S., Ternier, G., Pigny, P., Catteau-Jonard, S., Simon, V., et al. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.01.004 · Cited by 253
FAD-dependent lysine-specific demethylase-1 regulates cellular energy expenditure
Hino, S., Sakamoto, A., Nagaoka, K., Anan, K., Wang, Y., Mimasu, S., Umehara, T., Yokoyama, S., Kosai, K.-I., & Nakao, M. (2012) · Nature Communications · doi:10.1038/ncomms1755 · Cited by 226
Epigenetics of stress adaptations in the brain
Stankiewicz, A. M., Swiergiel, A. H., & Lisowski, P. (2013) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2013.07.003 · Cited by 220
Falahat, R., Berglund, A., Putney, R. M., Perez-Villarroel, P., Aoyama, S., Pilon-Thomas, S., Barber, G. N., & Mulé, J. J. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2013598118 · Cited by 190
“Unlike genetic alterations, epigenetic suppressions are potentially reversible by selective epigenetic reprogramming (23).”
BackgroundMarek, M., Kannan, S., Hauser, A.-T., Moraes Mourão, M., Caby, S., Cura, V., Stolfa, D. A., Schmidtkunz, K., Lancelot, J., Andrade, L., et al. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003645 · Cited by 173
Super-enhancers in transcriptional regulation and genome organization
Wang, X., Cairns, M. J., & Yan, J. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz1038 · Cited by 154
Mann, D. A. (2014) · Hepatology · doi:10.1002/hep.27131 · Cited by 153
Epigenetics in Alzheimer’s Disease: Perspective of DNA Methylation
Qazi, T. J., Quan, Z., Mir, A., & Qing, H. (2018) · Molecular Neurobiology · doi:10.1007/s12035-016-0357-6 · Cited by 153
Epigenetic modifications: Key players in cancer heterogeneity and drug resistance
Sadida, H. Q., Abdulla, A., Marzooqi, S. A., Hashem, S., Macha, M. A., Akil, A. S. A.-S., & Bhat, A. A. (2024) · Translational Oncology · doi:10.1016/j.tranon.2023.101821 · Cited by 151
Interplay between Epigenetics and Genetics in Cancer
Choi, J. D., & Lee, J.-S. (2013) · Genomics & Informatics · doi:10.5808/gi.2013.11.4.164 · Cited by 131
Wong, P., Hattangadi, S. M., Cheng, A. W., Frampton, G. M., Young, R. A., & Lodish, H. F. (2011) · Blood · doi:10.1182/blood-2011-03-341404 · Cited by 120
Mapping epigenetic modifications by sequencing technologies
Chen, X., Xu, H., Shu, X., & Song, C.-X. (2025) · Cell Death & Differentiation · doi:10.1038/s41418-023-01213-1 · Cited by 105
Regulation of habit formation in the dorsal striatum
Malvaez, M., & Wassum, K. M. (2018) · Current Opinion in Behavioral Sciences · doi:10.1016/j.cobeha.2017.11.005 · Cited by 96
Interactions between epigenetics and metabolism in cancers
Yun, J., Johnson, J. L., Hanigan, C. L., & Locasale, J. W. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00163 · Cited by 82
“Recently, four drugs that target the epigenetic machinery have been approved by the FDA for cancer treatment and have demonstrated prolonged survival and lower toxicity than conventional chemotherapy (Kelly et al., 2010; Baylin and Jones, 2011).”
BackgroundEpigenetic mechanisms in irritable bowel syndrome
Mahurkar-Joshi, S., & Chang, L. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00805 · Cited by 59
Habits are negatively regulated by histone deacetylase 3 in the dorsal striatum
Malvaez, M., Greenfield, V. Y., Matheos, D. P., Angelillis, N. A., Murphy, M. D., Kennedy, P. J., Wood, M. A., & Wassum, K. M. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2018.01.025 · Cited by 56
Ikehata, M., Ogawa, M., Yamada, Y., Tanaka, S., Ueda, K., & Iwakawa, S. (2014) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b13-00574 · Cited by 42
HDAC in obesity: A critical insight
Nijhawan, P., Behl, T., Khullar, G., Pal, G., Kandhwal, M., & Goyal, A. (2020) · Obesity Medicine · doi:10.1016/j.obmed.2020.100212 · Cited by 13
Latendresse, S. J., Musci, R., & Maher, B. S. (2018) · Prevention Science · doi:10.1007/s11121-017-0785-1 · Cited by 12
Identification of four novel hub genes as monitoring biomarkers for colorectal cancer
Luo, D., Yang, J., Liu, J., Yong, X., & Wang, Z. (2022) · Hereditas · doi:10.1186/s41065-021-00216-7 · Cited by 10
Metadata
- Authors
- Kelly, T. K., De Carvalho, D. D., & Jones, P. A.
- Venue
- Nature Biotechnology
- Published
- 2010-10
- Volume
- 28
- Issue
- 10
- Pages
- 1069-1078
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- OpenAlex
- W2089626640
- Cited by
- 793
- References
- 116
- FWCI
- 24.34
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.